

2006385

**Thrombotic Risk Reflexive Panel**

**THROMRISKR**

**Specimen Required:** Patient Prep: Fasting preferred. Refer to Specimen Handling at aruplab.com for hemostasis/thrombosis specimen handling guidelines.  
Collect: Four Light Blue (Sodium Citrate) **AND** two Lavender (EDTA) **AND** two Serum Separator Tubes (SST). Also acceptable in place of one of the Serum Separator Tubes (SST): Green (Sodium or Lithium Heparin) **or** EDTA (K<sub>2</sub> or K<sub>3</sub>).  
Specimen Preparation: One Serum Separator Tube (SST), Green (Sodium or Lithium Heparin) or EDTA (K<sub>2</sub> or K<sub>3</sub>) must be centrifuged and serum or plasma separated within 1 hour of collection. Transfer 1 mL centrifuged serum or plasma to ARUP Standard Transport Tube and label centrifuged tube for homocysteine testing. (Min: 0.5 mL) **AND** Transfer 2 mL serum into 2 ARUP Standard Transport Tubes, label as serum. (Min: 0.5 mL/tube) **AND** Transfer 7.5 mL platelet poor plasma prepared from the sodium citrate tubes to 5 ARUP Standard Transport Tubes, label as sodium citrate. (Min: 1 mL/tube) **AND** Transfer 3 mL lavender whole blood to 2 ARUP Standard Transport Tubes. (Min: 1 mL/tube)  
Storage/Transport Temperature: **Light Blue (Sodium Citrate):** CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.  
**Lavender Whole Blood and Serum, Green (Sodium or Lithium Heparin) or EDTA (K<sub>2</sub> or K<sub>3</sub>):** Refrigerated.  
Unacceptable Conditions: Specimens collected in any tube type not listed above.  
Stability (collection to initiation of testing): **Light Blue (Sodium Citrate):** Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 2 weeks  
**Lavender Whole Blood:** Ambient: 2 hours; Refrigerated: 1 week; Frozen: Unacceptable  
**Serum:** Ambient: 2 hours; Refrigerated: 1 week; Frozen: 2 weeks  
**Green (Sodium or Lithium Heparin) or EDTA (K<sub>2</sub> or K<sub>3</sub>):** Ambient: **4 days**; Refrigerated: **1 month**; Frozen: **10 months**

**Reference Interval:**

Test Number	Components	Reference Interval		
	Prothrombin Time	12.0-15.5 seconds		
	Dilute Russell Viper Venom Time (dRVVT)	33-44 seconds		
	Dilute Russell Viper Venom (dRVVT) 1:1 Mix (performed if dRVVT > 44 seconds)	33-44 seconds		
	Dilute Russell Viper Venom Time (dRVVT) Confirmation Test (performed if dRVVT 1:1 Mix > 44 seconds)	Negative		
	Partial Thromboplastin Time	32-48 seconds		
	Thrombin Time	14.7-19.5 seconds		
	Reptilase Time	Less than 22.0 seconds		
	PTT Heparin Neutralized	32-48 seconds		
	Partial Thromboplastin Time 1:1 Mix (performed if PTT > 48 seconds)	32-48 seconds		
	Platelet Neutralization Procedure (performed if PTT 1:1 Mix > 48 seconds)	Negative		
	Hexagonal Phospholipid Neutralization	Negative		
0050901	Cardiolipin Antibody, IgG	Effective August 18, 2014		
		0-14 GPL	Negative	
		15-19 GPL	Indeterminate	
		20-80 GPL	Low to Moderately Positive	
		81 GPL or above	High Positive	
0050902	Cardiolipin Antibody, IgM	Effective August 18, 2014		
		0-12 MPL	Negative	
		13-19 MPL	Indeterminate	
		20-80 MPL	Low to Moderately Positive	
		81 MPL or above	High Positive	
	Beta-2 Glycoprotein 1 Antibody, IgG	Effective August 18, 2014 0-20 SGU		
	Beta-2 Glycoprotein 1 Antibody, IgM	Effective August 18, 2014 0-20 SMU		
0098894	Protein S Free, Antigen	<b>Age</b>	<b>Male</b>	<b>Female</b>
		1-89 days	15-55%	15-55%
		90-179 days	35-92%	35-92%
		180-364 days	45-115%	45-115%
		1-5 years	62-120%	62-120%
		6-9 years	62-130%	62-130%
		10-17 years	60-140%	60-140%
		18 years and older	74-147%	55-123%
0099869	Homocysteine, Total	Effective January 4, 2021		
		0-15 µmol/L, for both male and female		
0030010	Antithrombin, Enzymatic (Activity)			

HOTLINE: Effective January 4, 2021

		<table border="1"> <thead> <tr> <th>Age</th> <th>Reference Interval</th> </tr> </thead> <tbody> <tr><td>1-4 days</td><td>39-87%</td></tr> <tr><td>5-29 days</td><td>41-93%</td></tr> <tr><td>30-89 days</td><td>48-108%</td></tr> <tr><td>90-179 days</td><td>73-121%</td></tr> <tr><td>180-364 days</td><td>84-124%</td></tr> <tr><td>1-5 years</td><td>82-139%</td></tr> <tr><td>6 years</td><td>90-131%</td></tr> <tr><td>7-9 years</td><td>90-135%</td></tr> <tr><td>10-11 years</td><td>90-134%</td></tr> <tr><td>12-13 years</td><td>90-132%</td></tr> <tr><td>14-15 years</td><td>90-131%</td></tr> <tr><td>16-17 years</td><td>87-131%</td></tr> <tr><td>18 years and older</td><td>76-128%</td></tr> </tbody> </table>	Age	Reference Interval	1-4 days	39-87%	5-29 days	41-93%	30-89 days	48-108%	90-179 days	73-121%	180-364 days	84-124%	1-5 years	82-139%	6 years	90-131%	7-9 years	90-135%	10-11 years	90-134%	12-13 years	90-132%	14-15 years	90-131%	16-17 years	87-131%	18 years and older	76-128%
Age	Reference Interval																													
1-4 days	39-87%																													
5-29 days	41-93%																													
30-89 days	48-108%																													
90-179 days	73-121%																													
180-364 days	84-124%																													
1-5 years	82-139%																													
6 years	90-131%																													
7-9 years	90-135%																													
10-11 years	90-134%																													
12-13 years	90-132%																													
14-15 years	90-131%																													
16-17 years	87-131%																													
18 years and older	76-128%																													
0030113	Protein C, Functional	<p>Effective November 17, 2014</p> <table border="1"> <thead> <tr> <th>Age</th> <th>Reference Interval</th> </tr> </thead> <tbody> <tr><td>1-4 days</td><td>17-53%</td></tr> <tr><td>5-29 days</td><td>20-64%</td></tr> <tr><td>30-89 days</td><td>21-65%</td></tr> <tr><td>90-179 days</td><td>28-80%</td></tr> <tr><td>180-364 days</td><td>37-81%</td></tr> <tr><td>1-6 years</td><td>40-92%</td></tr> <tr><td>7-9 years</td><td>70-142%</td></tr> <tr><td>10-11 years</td><td>68-143%</td></tr> <tr><td>12-13 years</td><td>66-162%</td></tr> <tr><td>14-15 years</td><td>69-170%</td></tr> <tr><td>16-17 years</td><td>70-171%</td></tr> <tr><td>18 years and older</td><td>83-168%</td></tr> </tbody> </table>	Age	Reference Interval	1-4 days	17-53%	5-29 days	20-64%	30-89 days	21-65%	90-179 days	28-80%	180-364 days	37-81%	1-6 years	40-92%	7-9 years	70-142%	10-11 years	68-143%	12-13 years	66-162%	14-15 years	69-170%	16-17 years	70-171%	18 years and older	83-168%		
Age	Reference Interval																													
1-4 days	17-53%																													
5-29 days	20-64%																													
30-89 days	21-65%																													
90-179 days	28-80%																													
180-364 days	37-81%																													
1-6 years	40-92%																													
7-9 years	70-142%																													
10-11 years	68-143%																													
12-13 years	66-162%																													
14-15 years	69-170%																													
16-17 years	70-171%																													
18 years and older	83-168%																													
	APC Resistance Profile	<p>Effective February 21, 2011 2.00 or greater</p> <table border="1"> <thead> <tr> <th>Test Number</th> <th>Components</th> <th>Reference Interval</th> </tr> </thead> <tbody> <tr> <td>0030127</td> <td>APC Resistance Profile</td> <td>Refer to report</td> </tr> <tr> <td>0097720</td> <td>Factor V Leiden (F5) R506Q Mutation</td> <td>Refer to report</td> </tr> </tbody> </table>	Test Number	Components	Reference Interval	0030127	APC Resistance Profile	Refer to report	0097720	Factor V Leiden (F5) R506Q Mutation	Refer to report																			
Test Number	Components	Reference Interval																												
0030127	APC Resistance Profile	Refer to report																												
0097720	Factor V Leiden (F5) R506Q Mutation	Refer to report																												
	Factor V Leiden by PCR & Fluorescence Monitoring	Negative: The sample is negative for factor V Leiden, R506Q mutation.																												
0056060	Prothrombin (F2) c.*97G>A (G20210A) Pathogenic Variant																													